Calcium Channel Blocker-Associated Chyloperitoneum in Patients Receiving Peritoneal Dialysis: A Systematic Review

Unlike chyloperitoneum associated with clinical conditions including cancer, cirrhosis, and traumatic surgery, calcium channel blocker (CCB)-associated chyloperitoneum is rarely discussed in comprehensive studies on chyloperitoneum. We aimed to investigate the prevalence and characteristics of CCB-a...

Full description

Saved in:
Bibliographic Details
Published in:International journal of environmental research and public health 2019-04, Vol.16 (8), p.1333
Main Authors: Kim, Seungyeon, Yu, Yun Mi, Kwon, Jeongyoon, Yoo, Hyejin, Jung, Sun Hoi, Lee, Euni
Format: Article
Language:English
Subjects:
Antibiotics
Blood pressure
Calcium
Calcium channel blockers
Cardiovascular diseases
Diagnostic systems
Dialysis
Drugs
End-stage renal disease
FDA approval
Food safety
Full text
Health care
Hypertension
Kidney diseases
Mortality
Patients
Peritoneal dialysis
Peritoneum
Peritonitis
Population studies
Regulatory agencies
Researchers
Review
Studies
Systematic review
Tomography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Unlike chyloperitoneum associated with clinical conditions including cancer, cirrhosis, and traumatic surgery, calcium channel blocker (CCB)-associated chyloperitoneum is rarely discussed in comprehensive studies on chyloperitoneum. We aimed to investigate the prevalence and characteristics of CCB-associated chyloperitoneum in peritoneal dialysis (PD) patients. The MEDLINE, Embase, CENTRAL, CiNii, and RISS databases were systematically searched for clinical studies on CCB-associated chyloperitoneum in PD patients published up to 31 July 2018. A total of 17 studies (four cohort studies, one case series, and 12 case reports) were selected. Eight CCBs, namely amlodipine, benidipine, diltiazem, lercanidipine, manidipine, nifedipine, nisoldipine, and verapamil, were reported to be associated with chyloperitoneum; manidipine and lercanidipine were the most frequently reported. The average prevalence of chyloperitoneum for lercanidipine was 25.97% in three cohort studies, two of which had a moderate or high risk of bias. Most of the studies revealed chyloperitoneum development within 4 days of initiation of CCB therapy and chyloperitoneum disappearance within 24 h of CCB withdrawal. The results of this study emphasise on the need for awareness among healthcare professionals regarding CCB-associated chyloperitoneum in PD patients. Further studies elucidating the causality and clinical implication of CCB-associated chyloperitoneum are needed.
ISSN:1660-4601
1661-7827
1660-4601
DOI:10.3390/ijerph16081333